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Epidemiology
There are few routine data 
on the health of South 
African (SA) adolescents 
(defined by the World Health 
Organization (WHO) as aged 10 - 19 years), 
partly a result of the age bands used in the 
District Health Information System. This is 
cause for concern. Many of the determinants 
of adult ill health, such as harmful alcohol 
use, tobacco use, unhealthy diet, and lack 
of physical activity, have their origins in 
adolescence. Critically, female adolescents 
bear a disproportionate burden of the HIV 
epidemic in SA. In 2012, the estimated 
HIV prevalence (range) in 15 - 24-year-old 
SA women and men was 13.9% (12.9 - 
16.8%) and 3.9% (2.5 - 5.7%), respectively,[1] 
equating to ~720 000 adolescents and young 
people living with HIV.[2] The population 
of adolescents living with HIV in SA is 
comprised of adolescents with perinatal 
HIV infection (PHIV) who have moved into 
adolescence (PHIA) and those who acquired 
HIV at an older age through sexual activity, 
intravenous drug use or other less common 
modes of transmission (non-PHIV).  
The prevention of mother-to-child-
transmission programme (PMTCT) in SA 
has led to a massive reduction in perinatal 
HIV infections in the last decade. As 
a result, combined with high coverage and 
early initiation of combination antiretroviral 
therapy (ART) with concomitant reductions 
in morbidity and mortality, the SA population 
of children with perinatally acquired HIV 
is rapidly moving into adolescence, with 
adolescents possibly already forming the bulk of 
paediatric HIV patients.[3] Some PHIA will have 
been diagnosed with HIV and started on ART 
early in childhood, with some already on second- 
or third-line ART by the time they reach 
adolescence. Other PHIA who are diagnosed 
in late childhood or in early to mid-adolescence 
are often severely immunocompromised and 
urgently require ART at the time of diagnosis, 
though up to half may be asymptomatic.[4] 
These late presenters represent ongoing 
missed diagnostic opportunities, the result of 
numerous factors beyond the scope of this 
article, but which include poor record keeping 
contributing to subtle chronic symptoms not 
being appropriately identified or investigated 
by healthcare workers despite numerous clinic 
visits, and the lack of child- or youth-friendly 
services hampering accessibility. 
The prevention and diagnosis of HIV 
infection acquired in adolescence continues 
to require urgent attention. Nearly a quarter 
(24%) of all new HIV infections in SA in 
2012 occurred in 15 - 24-year-olds, with the 
incidence in women in this age group almost 
4 times greater than that in men (2.5% v. 
0.6%).[2] Adolescents living with HIV acquired 
during adolescence are likely to have early-
stage disease, higher CD4+ counts, and fewer 
opportunistic infections, and are less likely to 
meet current criteria for initiation of ART than 
PHIA. An exception is pregnant adolescents, 
who would qualify for ART regardless of 
CD4+ count and time of infection. Measures 
to address HIV testing and access to care in 
children and adolescents are imperative. 
Combination ART and 
monitoring 
Table 1 tabulates the indications for ART 
initiation in adolescents. Table 2 describes 
first-, second- and third-line regimens 
currently used in adolescents. 
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Table 1. Criteria for ART initiation in ALHIV
Criteria for initiation of ART in ALHIV
Criteria for fast-tracking (starting ART within 
7 days of being eligible)
WHO stage 3 or 4 CD4+ count of ≤200 cells/mm3
CD4+ count ≤500 cells/mm3 WHO stage 4 disease
Pregnancy or breastfeeding (PMTCT started 
urgently)
MDR/XDR-TB
ART = antiretroviral therapy; ALHIV = adolescents living with HIV; WHO = World Health Organization; 
PMTCT = prevention of mother-to-child transmission; 
MDR/XDR-TB = multidrug-resistant/extensively drug-resistant tuberculosis.
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Monitoring of clinical, immunological 
and virological indicators on ART for 
adolescents is the same as for children. 
In addition, given the high risks of poor 
adherence and virological failure in this 
group, 6-monthly viral load (VL) testing 
should be considered.
Outcomes on ART
Longitudinal cohorts, mainly from well-
resourced settings, report good clinical 
health with weight, height and body mass 
index approximating population norms.[5] 
Reductions in mortality rates of up to 76% 
in PHIV children and adolescents receiving 
ART have been reported in well-resourced 
settings.[6] All-cause mortality rates are 
similar when adolescents (9 - 19 years) 
and young adults receiving ART (20 - 
29 years) are compared in reports from 
sub-Saharan Africa.[7,8] Immunologically, 
cohorts from resource-rich and resource-
limited settings demonstrate robust CD4+ 
improvement on ART, sustained to at 
least 5 years of follow-up.[6,8] Adolescents, 
however, generally have lower virological 
suppression rates (HIV VL <400 copies/mL) 
on ART compared with adults. Suppression 
rates range between 27% and 78% in 
longitudinal cohorts with low rates in 
both PHIV and non-PHIV adolescents in 
sub-Saharan Africa.[8-10] Table 3 describes 
challenges with ART that are unique to 
adolescents.[11]
Adherence
Adolescence is a period of physical, sexual, 
emotional and psychological change 
associated with developing autonomy, 
increased impulsivity and risk taking, 
increased peer influence and potentially 
reduced parental oversight. Poor adherence 
in adolescence has been described in many 
chronic conditions including diabetes, 
asthma, cystic fibrosis and HIV. Poor 
adherence may be related to a number of 
factors including: simple lifestyle barriers 
such as forgetting or struggling to fit 
ART into a busy school and extramural 
schedule; medication-related factors such 
as complex twice-daily regimens with high 
pill burdens; drug-drug interactions, and 
side-effects; patient-related factors such 
as treatment fatigue, lack of disclosure 
to the adolescent and by the adolescent 
to others, fear of stigma, unresolved 
psychosocial problems or substance abuse; 
and socioeconomic constraints limiting 
access to the clinic. 
Since both adherence and barriers may 
change over time, it is necessary to assess 
adherence and modifiable barriers at each 
visit and, together with the adolescent, 
tailor interventions to support adherence 
(Table 4). At each visit the following 
adherence reinforcements are necessary: 
identify and resolve any confusion with the 
regimen; manage any emerging drug side-
effects; enquire about changes in lifestyle and 
need for adjustments; and provide ongoing 
psychosocial counselling and management of 
new or unresolved issues. A multidisciplinary 
approach including social workers, nurse, 
mental health professionals and counsellors 
may be required where available. 
Approach to an 
adolescent with 
virological failure 
An elevated HIV VL is the most sensitive, 
though not necessarily specific, measure of 
non-adherence in HIV-infected patients as 
individuals with significant non-adherence will 
have detectable VLs. However, highly adherent 
individuals may have elevated VLs as a result 
of drug resistance, inappropriate regimens, 
drug interactions or incorrect doses. VL blips 
are defined as an unexplained VL between 
50 and 1  000 copies/mL with VL suppression 
on repeat sampling, and are of limited clinical 
significance. Virological failure is defined as a 
VL >1 000 copies/mL on two consecutive assays 
taken at least 1 month apart from a patient on 
ART for at least 6 months. Virological failure 
precedes immunological failure which, in turn, 
usually precedes clinical failure, and allows early 
detection of adherence problems potentially 
prior to development of resistance mutations. 
Table 5 outlines management of ado lescents 
with virological failure. 
Not all adolescents with virological failure 
will have developed resistance. Resistance 
is more likely in regimens containing 
nevirapine, efavirenz and lamivudine as 
single mutations confer high-level resistance 
to these drugs. Since cross-resistance 
between nevirapine and efavirenz and 
other non-nucleoside reverse-transcriptase 
inhibitor (NNRTI) drugs occurs, adolescents 
failing an NNRTI-based regimen need to 
be switched to the standard second-line 
regimen as soon as possible to prevent 
accumulation of additional NRTI and/
or NNRTI resistance mutations that may 
compromise NRTIs and second-generation 
NNRTIs like etravirine that could be used 
in later regimens.[12] Adolescents can safely 
be switched to the second-line regimen 
without HIV drug-resistance testing (DRT) 
(if not available), as the resistance mutations 
are largely predictable if early switch occurs.[12] 
Adolescents with virological failure on a protease 
inhibitor (PI)-based regimen can continue 
intensive adherence counselling for longer 
Table 2. ART regimens in ALHIV
First-line regimen
Weight <40 kg or age <15 y ABC + 3TC + EFV*
Weight ≥40 kg, age ≥15 y and Tanner stage ≥3 Fixed-dose combination (FDC):† TEE 
(TDF + FTC‡ + EFV) 
Pregnant adolescents
Age >12 y and weight >40 kg FDC: TEE†
TDF + 3TC/FTC + EFV (individual drugs 
can be given and nevirapine can replace 
EFV)
Second-line regimen
If first-line regimen was:
ABC/TDF + 3TC/FTC + EFV
Recommended second-line regimen:
AZT +3TC + LPV/r 
Third-line regimen
Failing second-line regimen Consult a specialist
Regimen should be based on genotype 
resistance testing and expert opinion with 
supervised care
Access to third-line ART managed centrally 
by the National Department of Health Third 
Line Committee, email jamalk@health.gov.za
ART = antiretroviral therapy; ALHIV = adolescents living with HIV; ABC = abacavir; 3TC = lamivudine; EFV = efavirenz; 
TEE = tenofovir, emtricitabine and efavirenz; TDF = tenofovir; FTC=emtricitabine; AZT=zidovudine;
LPV/r = lopinavir/ritonavir. 
*Nevirapine can replace EFA if necessary.
†If FDC not used, individual drugs can be given.
‡3TC can replace FTC.
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periods to try to achieve virological suppression, as PIs have a high 
resistance barrier and are associated with less accumulation of NRTI 
resistance mutations even with high VLs >30 000 copies/mL.[12] Most 
patients with virological failure on a boosted PI will resuppress on 
this regimen with optimal adherence.
Where possible, it may be appropriate to have a specific clinic day 
with multidisciplinary team support for adolescents with adherence 
problems, virological failure and resistance. 
In some cases virological failure secondary to poor adherence may 
prove intractable despite adherence interventions, and the resultant 
immunological and clinical failure could constitute a relative 
emergency. In such instances a period of inpatient directly observed 
therapy should be considered to stabilise the adolescent, identify critical 
clinical, psychosocial and mental health issues, and  provide intensive 
interventions.[13] This should only be done in a multidisciplinary team 
setting in consultation with the adolescent and caregiver. 
Table 3. Challenges of ART treatment in PHIV adolescents*
Problem Implication Solution
Physiological
Rapid growth and puberty Exposure to inadequate ART dose as a 
result of growth 
Routine dose adjustment per weight and Tanner 
stage assessment
Weight stunting and delayed puberty Overdosage of ART with potentially 
increased toxicity 
Routine dose adjustment per weight and Tanner 
stage assessment
Orofacial motor abnormalities or lesions 
(e.g. candidiasis, poor dentition)
Difficulty with swallowing ART leading to 
decreased adherence
Select regimens with ART agents available in liquid 
or powder formulations (e.g. AZT, 3TC, ABC), or 
crushable or dissolvable, or allow the capsules to be 
opened (e.g. ATV, DRV, EFV, FTC, TDF)
Note: co-formulated agents cannot be crushed
Poor palatability Decreased adherence Same as above; consider masking taste using soda, 
juice, apple sauce
Adverse effects
GI intolerance (e.g. nausea, diarrhoea) Decreased adherence Take with meals
Alter timing of administration (e.g. night-time 
dosing)
Anti-emetic, antidiarrhoeal agents
Consider alternative regimen
Central nervous system side-effects (e.g. 
altered sensorium, dreams, headache) 
Decreased adherence Alter timing of administration (e.g. night-time 
dosing)
Consider alternative regimen
Change in physical appearance 
(e.g. scleral icterus with ATV, facial 
lipoatrophy with d4T)
Decreased adherence Consider alternative regimen
Drug-drug interactions
Rifampicin-based TB co-treatment with 
LPV/r
Suboptimal LPV levels Increased boosting with ritonavir or double dosing 
with LPV/r
Hormonal contraceptives and ritonavir-
boosted PIs
Suboptimal hormonal levels with 
increased risk of pregnancy
For females using ritonavir-boosted PIs and 
combination hormonal contraceptives (pills, 
patches and rings) or progestin-only pills, the use 
of an alternative contraceptive method with dual 
contraceptive method use is recommended
Comorbid conditions
Malaria, low nutritional status and 
advanced HIV disease
Increased risk of anaemia with certain 
ARVs (e.g. AZT)
Regular assessment of haemoglobin levels at 
initiation, 1 month, 3 months and then every 6 
months or symptomatic
Cognitive impairment due to HIV 
encephalopathy, longstanding HIV 
infection
Decreased adherence Simplified regimens, cognitive age-appropriate 
education, regimens with a high barrier to resistance 
Developmental stage
Concrete thinking and emotional 
immaturity
Decreased adherence Simplified regimens, cognitive age-appropriate 
education, regimens with a high barrier to resistance 
ART = antiretroviral therapy; PHIV = perinatally acquired HIV; AZT = zidovudine; 3TC= lamivudine; ABC=abacavir; ATV = atazanavir; DRV = darunavir; EFV = efavirenz; FTC = emtricitabine; 
TDF = tenofovir; GI = gastrointestinal; d4T=stavudine; TB = tuberculosis; LPV/r=lopinavir/ritonavir; PI = protease inhibitor.
*Adapted from Agwu and Fairlie.[11]
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Indications for HIV 
DRT 
The following are suggested criteria for DRT in 
adolescents: failing an NNRTI-based regimen 
for more than 1 year (although should ideally 
have been switched to a PI-based regimen 
earlier); or failing a boosted PI-based regimen 
(especially with a history of rifampicin-
based tuberculosis (TB) co-treatment). To 
optimise results, DRT should be done only if 
VL ≥1  000 copies/mL; and if the adolescent 
has received ART for at least the past 4 weeks. 
Unfortunately it may not be possible to ensure 
adherence, and thus drug pressure, at the time 
of DRT if the adolescent claims adherence to 
be good. This will limit the interpretability of 
DRT as the resistant viral subpopulation may 
not be at adequate levels required for the DRT. 
The current DRT and all previous DRTs need 
to be combined with the treatment history 
to guide new regimen choices in treatment-
experienced adolescents.  
Drug-drug interactions
Table 6 summarises the most important 
drug-drug interactions in children and 
adolescents. It is advisable to consult an 
up-to-date medicines formulary and 
available online resources (www.hivdrug-
interactions.org) prior to the prescription 
of any new agent where there is uncertainty 
about potential drug interactions.
ART side-effects and 
toxicities
Table 7 highlights the most significant side-
effects and toxicities in adolescents. The 
clinician needs to be aware of the risks of 
using tenofovir in adolescents <15 years of 
age and <40 kg weight, with a low glomerular 
filtration rate (GFR) and Tanner staging of 
≤3. Gynaecomastia, which is common 
in pubertal adolescent males in general, 
may be associated with efavirenz; careful 
management to avoid psychological 
distress and subsequent adherence 
problems is required.  
Table 4. Strategies to address non-adherence in HIV-infected adolescents
Medication-related barriers
Reduced pill burden (e.g. once daily/fixed-dose combinations)
Palatable formulations (liquid, powder, crushing)
Management of side-effects
Anti-nausea, anti-diarrhoeal agents
Change timing of dosing (e.g. night-time dosing)
Regimen change
Patient-related factors
Disclosure
Counselling to deal with loss/trauma
Treatment of concurrent psychiatric diagnosis (e.g. anxiety, depression, substance abuse)
Education about HIV and benefits of ART
Behavioural interventions
Motivational interviewing
Counselling, support groups
Life-skills education with time-management and prioritisation
Parental/caregiver involvement
Buddy systems
Adherence clubs
Peer motivators/educators
Activity triggers (e.g. meals)
Calendars
Technological interventions (e.g. cell phone, SMS texts, watches, beepers)
Pill boxes
Pharmacy clinic
Directly observed therapy
Structural barriers
Address barriers such as transportation, insurance, child care, clinic hours
Education of clinic staff about cognitive and development stage of adolescents
Adapted from Agwu and Fairlie.[11] 
Table 5. Management of VL results in adolescents
VL Response
Lower than detectable limit Congratulations! Adherence support/reinforcement as needed
Continue annual VL monitoring
<400 copies/mL Annual VL monitoring and adherence support
400 - 1 000 copies/mL Step-up adherence package
Repeat VL in 6 months
>1 000 copies/mL − 
virological failure
Adherence counselling/review 
 Full review of ART history including PMTCT, past regimens (duration and virological response), current regimen 
duration and response, CD4+ count and clinical stage
Repeat VL in 3 months 
• If <400, return to routine 6 - 12-monthly monitoring
• If 400 - 1 000, continue step-up adherence and repeat VL after 6 months
•  If NNRTI regimen and VL >1000 despite stepped-up adherence, switch to second-line therapy after adherence ensured
•  If PI regimen and VL >1 000 but <30  000 despite stepped-up adherence, continue with same regimen while 
monitoring VL every 3 months
• Continue stepping up adherence and consult an expert 
• If PI regimen and VL >30 000, refer to an expert for further management
VL = viral load; ART = antiretroviral therapy; PMTCT = prevention of mother-to-child transmission; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
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Disclosure to adolescents
In order to fulfil their developing autonomy adolescents require 
accurate information regarding their health, including their HIV 
status. WHO recommends that disclosure occurs before 12 years 
of age, but this needs to be applied to each individual context.[14] 
Consideration of the maturity and level of insight is essential. A child 
who enquires about their treatment and their health indicates a desire 
for further information and a need to start the disclosure process. 
Disclosure should be complete long before sexual activity begins. 
Disclosure may result in improved adherence, acceptance of the 
diagnosis and improved clinical outcomes.[15] Moreover, disclosure of 
maternal HIV status to the child may strengthen the relationship and 
build trust between mother and child.[16] 
Caregivers need supportive counselling in order to prepare them 
for the disclosure process. Disclosure is not a once-off event, but 
a process, built on a foundation of health education, aiming to 
teach the child about maintaining their health, understanding their 
condition and beginning to take ownership of their own healthcare. 
Disclosure is never urgent, and is best done by the caregiver 
after adequate preparation. Many tools are available for facilitating 
Table 6. Antiretroviral drug interactions for agents commonly used for the management of adolescents living with HIV
Drug class Drug ARV interacts Effect of interaction Management of interaction
Antibiotics Rifampicin LPV/r Reduced level of EFV Superboost with additional RTV, to bring 
the ratio of LPV:RTV to 1:1 or double the 
LPV/r dose if RTV not available
NVP Cumulative toxicity, may have 
reduced NVP levels
Avoid concurrent use
Clarithromycin EFV Reduced level of 
clarithromycin
Avoid concurrent use; consider 
azithromycin as an alternative
AZT Reduced level of AZT if 
administered together
Give clarithromycin and AZT at least 
2 hours apart
Aminoglycosides TDF Cumulative renal toxicity Avoid concurrent use where possible; 
monitor renal function and discuss with 
expert where necessary
Antifungals Fluconazole NVP Elevated NVP levels, 
may have cumulative 
hepatotoxicity
Monitor for NVP side-effects
Anticonvulsants Carbamazepine
Phenytoin
Phenobarbitone
PIs, NNRTIs Altered ART drug levels Valproate/lamotrigine are preferred 
anticonvulsants in combination with ART
Valproate AZT Increased AZT level Monitor for AZT side-effects; consider 
alternatives
Psychotropic drugs Benzodiazepines (NB 
midazolam, triazolam)
PIs Delayed clearance of the 
benzodiazepine may result in 
increased sedation
Lorazepam is the preferred agent
Fluoxetine
Paroxetine
PIs Drug levels may increase to 
dangerous level
Avoid concurrent use – citalopram 
preferred.
Contraceptives Oral contraceptives 
(COCs, POPs)
PIs, NNRTIs Contraceptive efficacy may 
be reduced
Avoid concurrent use. Strongly reinforce 
condom use and advise on alternative 
methods (IUCD or injectable)
Others Warfarin NNRTIs, PIs Warfarin level altered Monitor INR closely and adjust warfarin 
dose accordingly
Corticosteroids 
(NB: fluticasone, 
budesonide)
PIs Increased level of 
corticosteroids
Monitor closely for systemic effects of 
corticosteroids; consider dose reduction
Simvastatin and 
lovastatin
PIs Increased level – may lead to 
dangerously toxic levels
Consider substitution with low-dose 
atorvastatin (in consultation with an expert)
Ergotamine PIs Increased level, may lead to 
toxicity
Avoid concurrent use
St John’s wort PIs, NNRTIs Reduces levels of 
antiretroviral agents
Avoid concurrent use
ARV = antiretroviral; LPV/r=lopinavir/ritonavir; EFV = efavirenz; RTV = ritonavir; NVP = nevirapine; AZT = zidovudine; TDF = tenofovir; PI = protease inhibitor; 
NNRTI = non-nucleoside reverse transcriptase inhibitor; COCs = combined oral contraceptives; POPs = progestin-only pills; IUCD = intrauterine contraceptive device; 
INR = international normalised ratio.  
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disclosure, including talking books, picture books and comic books, 
some aimed at educating the adolescent, others guiding the caregiver. 
Adolescents also require support in connection with disclosing to 
sexual partners, friends, parents or any other individual, if and when 
this becomes desirable.
Transition to adult care 
Transition of adolescents from child-focused care to adult-focused 
care may involve physical transfer to a different clinical space or 
may be a developmental shift with the adolescent moving from a 
supported to an independent, autonomous role within the same 
clinic. Regardless, planning to ensure safe and successful transition 
is required, as transition may be accompanied by significant 
anxiety and may result in disruption of care. All adolescents 
who transition to adult care must have undergone a disclosure 
process with ongoing support, information and reassurance.[17] 
Full communication to the adult-care practitioner, of all previous 
medical, sexual and reproductive health and psychosocial history, 
is essential. Ongoing attention to sexual and reproductive health 
needs, particularly access to contraception, is important for the 
transitioning adolescent.
In settings receiving these transitioning youth, familiarity with the 
complexities of managing HIV-infected youth from a medical and 
psychosocial perspective, a multidisciplinary team with co-ordination 
of all aspects of care, and appropriate linkage to other services 
including sexual and reproductive health services, psychological and 
psychiatric care are required.[17] 
In conclusion, although many adolescents living with HIV have 
good outcomes on ART, adolescence is a high-risk period for non-
adherence and associated virological failure. Clinicians need to be 
aware of adolescent-associated problems, and mechanisms to assist 
this population with a successful transition to adult care. 
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